China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with New Zealand-headquartered AFT Pharmaceuticals Limited, a leading healthcare product manufacturer and distributor. The agreement pertains to Brimochol PF, a fixed dose of carbachol and bromonidine tartrate that is preservative free, co-developed by Tenpoint Therapeutics Ltd.
Agreement Details
Under the terms of the agreement, Zhaoke will grant AFT exclusive rights to import, distribute, promote, market, and sell Brimochol PF in Australia and New Zealand. AFT will also be responsible for obtaining the necessary local regulatory licenses as part of the deal. In return, Zhaoke will receive an undisclosed upfront payment and is eligible for additional milestone payments upon achieving certain predefined objectives.
Brimochol PF: Clinical Efficacy and Regulatory Pathway
Brimochol PF is indicated for the correction of loss of close-range vision due to presbyopia. The drug demonstrated significant improvement in patients’ 8-hour close-range vision in the pivotal BRIO-II study, successfully reaching the pre-set primary endpoint. Building on these positive results, a New Drug Application (NDA) for Brimochol PF is anticipated to be filed in the US during the first half of this year, marking a crucial step in its global regulatory journey.-Fineline Info & Tech
